SYHA1811 / CSPC Pharma - LARVOL DELTA

CSPC’s Cat 1 SYHA1811 nails trial nod in China (GBI Health) - "China-based CSPC Pharmaceutical Group Limited (01093.HK) announced that its Category 1 drug SYHA1811 has been approved for clinical study in relapsed/refractory B-cell lymphoma including but not limited to mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic leukemia, Waldenstrom's macroglobulinemia, marginal zone lymphoma Tumor, follicular lymphoma, diffuse large B-cell lymphoma, and more."

Non-US regulatory • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma